Far from the big hubs, Apel­lis is steer­ing its ri­val to Alex­ion's Soliris in­to a PhI­II pro­gram

A Ken­tucky biotech says they’re lay­ing the foun­da­tion for a piv­otal pro­gram for their C3 in­hi­bi­tion ther­a­py, which ex­ecs be­lieve can re­place Soliris in treat­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER